Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of zeartinib in preparation of drugs for treating pulmonary fibrosis diseases

A technology for pulmonary fibrosis and disease, applied in the field of application of zanubrutinib in the preparation of drugs for the treatment of pulmonary fibrosis

Active Publication Date: 2021-02-23
TIANJIN JIKUN MEDICAL TECH CO LTD
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are no reports of zanubrutinib slowing down pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of zeartinib in preparation of drugs for treating pulmonary fibrosis diseases
  • Application of zeartinib in preparation of drugs for treating pulmonary fibrosis diseases
  • Application of zeartinib in preparation of drugs for treating pulmonary fibrosis diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1: Zanubrutinib slows down bleomycin-induced pulmonary fibrosis in mice

[0030] Animal model preparation: male C57BL / 6J wild-type mice (8-10 weeks old), anesthetized mice, and invasively injected 2U / Kg bleomycin into the trachea.

specific Embodiment approach

[0031] The specific implementation method is as follows: weigh and record after anesthetizing the mouse, fix the mouse on the operating table, disinfect the neck with 75% (v / v) alcohol, and cut a vertical wound of about 1 cm in the neck of the mouse with a scalpel. Use microscopic tweezers to separate the tissues to expose the trachea, insert the syringe into the trachea through the gap between the cartilage rings of the trachea towards the end of the heart, then slowly inject 2 U / kg of bleomycin saline solution in a volume appropriate to its body weight, and immediately put the animal upright And rotate left and right, so that the liquid medicine is evenly distributed in the lungs.

[0032] The blank control group was injected with the same volume of normal saline (0.9% (w / v) NaCl (sodium chloride)).

[0033] Administration in groups: Zenubrutinib treatment refers to giving mice 10 mg / kg of zanubrutinib by intragastric administration every day on the 7th to 14th day of bleomy...

Embodiment 2

[0035] The same as in Example 1, the difference is: in group administration: on the 7th-14th day of bleomycin treatment, mice were given 5 mg / kg zanubrutinib by intragastric administration every day, and the corresponding solvent saline was used as a control , 14 days after bleomycin treatment, lung collagen content and fibrosis severity were detected.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The embodiment of the invention provides an application of zeartinib in preparation of drugs for treating pulmonary fibrosis diseases, and the structural formula of zeartinib is shown in the specification. Experiments show that zeartinib has a good effect on pulmonary fibrosis, has no adverse reaction, can slow down bleomycin-induced pulmonary fibrosis in mice, and provides a good application prospect for the treatment, alleviation or improvement of pulmonary fibrosis diseases.

Description

technical field [0001] The invention relates to a use of zanubrutinib, in particular to the application of zanubrutinib in the preparation of medicines for treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis (PF) is the end-stage clinical manifestation of many pulmonary interstitial diseases with different etiologies, characterized by persistent alveolar damage, fibroblast proliferation, and massive extracellular matrix (ECM) deposition , leading to varying degrees of inflammation and fibrosis in the alveoli and interstitium of the lungs, leading to structural destruction of the lungs and respiratory failure, so it is also called interstitial lung disease (Interstitial Lung Disease, ILD) or diffuse parenchymal Lung disease (Diffuse Parenchymal Lung Disease, DPLD). [0003] Idiopathic pulmonary fibrosis (IPF) belongs to the idiopathic interstitial pneumonia (IIP) group in the family of interstitial lung diseases (ILDs). IPF is the most common and s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61P11/00
CPCA61K31/519A61P11/00
Inventor 杨诚周红刚李霄鹤张亮李建伦东超
Owner TIANJIN JIKUN MEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com